Engrail Therapeutics, Inc.
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
12750 High Bluff Dr Ste 190, San Diego, ...Phone Number
(858) 868-1292Website
www.engrail.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
2
2
1
1
1
1
About Engrail Therapeutics, Inc.
Engrail Therapeutics is a neuroscience research company developing transformative medicines to reduce the enormous burden of diseases that impact the nervous system. The company is based in San Diego, California.Explore more
Engrail Therapeutics, Inc. Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Engrail Therapeutics, Inc. your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Engrail Therapeutics, Inc. has recently received funding, and reach out quickly before it becomes old news!
Engrail Therapeutics, Inc., which may be a good buyer, showed buying intent in Masked Content Topic
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Engrail Therapeutics, Inc. recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at Engrail Therapeutics, Inc.
Product Launch: Get notified when Engrail Therapeutics, Inc. launches new products
Check out if Engrail Therapeutics, Inc. is spiking on competitors!
Funding: Get notified immidiatlly once Engrail Therapeutics, Inc. has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Engrail Therapeutics, Inc. had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined Engrail Therapeutics, Inc. as Masked Content
Find 3 more new buyers
Compare Similar Companies to Engrail Therapeutics, Inc.
Compare insights from companies similar to Engrail Therapeutics, Inc., focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Engrail Therapeutics, Inc. is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
Engrail Therapeutics, Inc. is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about Engrail Therapeutics, Inc..
Engrail Therapeutics, Inc. financials insights
Gather financial insights about Engrail Therapeutics, Inc., including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2021
Series A
$64M
2024
Series B
$157M
Engrail Therapeutics, Inc. Tech Stack
A closer look at the technologies used by Engrail Therapeutics, Inc.
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
Executive Move
Executive Moves, Board of Directors
Funding
Engrail Therapeutics, Inc. News & Media
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of Directors
Engrail Therapeutics Appoints Paul Cayer as Chief Financial Officer and Saira Ramasastry to Board of DirectorsEngrail Therapeutics Closes Oversubscribed $157M Series B Financing Round to Advance the Development of Transformational Therapies
SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the development of transformational therapies to improve the lives of patients, today announced the close of an oversubscribed $157 million Series B financing round. The round was co-led by new investors F-Prime Capital, Forbion, and Norwest Venture Partners, with participation from RiverVest Venture Partners, Red Tree Venture Capital, funds managed by abrdn Inc., Ysios CapitalEngrail Therapeutics Initiates the ENCALM Phase 2 Clinical Trial of ENX-102 in Patients with Generalized Anxiety Disorder
SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, today announced initiation of a multi-center phase 2 clinical trial, the ENCALM Trial, to evaluate the efficacy and safety of ENX-102 in patients with generalized anxiety disorder (GAD). ENX-102 is an investigational, highly selective GABA-A α2,3,5 positive allosteric modulator (PAM) and antagoniEngrail Therapeutics Announces Positive Results of ENX-101 Phase 1b Clinical Study and Prepares for Initiation of ENACT Phase 2 Trial in Focal Epilepsy
SAN DIEGO--(BUSINESS WIRE)--Engrail Therapeutics™ (Engrail) (the Company), a precision neuroscience company focused on the acquisition, development, and commercialization of transformational therapies, has announced positive results from a phase 1b clinical trial of ENX-101, a subtype-selective GABA-A positive allosteric modulator (PAM). The phase 1b clinical trial data were presented on June 6, 2022, at the 2022 Epilepsy Pipeline Conference in Santa Clara, California. Following these results a
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Engrail Therapeutics, Inc.
Sign Up For FreeTo access detailed company insights
Engrail Therapeutics is a neuroscience research company developing transformative medicines to reduce the enormous burden of diseases that impact the nervous system. The company is based in San Diego, California.... Read More
